Posted by Michael Wonder on 26 Jul 2024
MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults
23 July 2024 - Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease.
The MHRA has today approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes.
